Lappe R W, Todt J A, Wendt R L
J Pharmacol Exp Ther. 1986 Jan;236(1):187-91.
The effects of fenoldopam, a selective dopamine-1 agonist, on regional blood flow and vascular resistance were examined in conscious unrestrained spontaneously hypertensive rats (SHR). Rats were instrumented chronically with pulsed Doppler flow probes to allow measurement of renal, mesenteric and hindquarters blood flow. Maximal changes in mean arterial pressure, heart rate and regional blood flow were recorded after i.v. administration of fenoldopam (1-1000 micrograms/kg). Fenoldopam produced a dose-dependent reduction in arterial pressure and increased heart rate in the conscious SHR. Significant increases in mesenteric (maximal = 69 +/- 10%) and renal (maximal = 42 +/- 4%) blood flows were observed at all doses of fenoldopam. In the hindquarters, vascular resistance was increased after low doses of fenoldopam (1-30 micrograms/kg), but decreased with higher doses (100-1000 micrograms/kg). After ganglionic blockade, hindquarter vasodilation was observed with fenoldopam at low (10 micrograms/kg) and high (500 micrograms/kg) doses. Pretreatment with metoclopramide (20 mg/kg) or SCH 23390 (30 micrograms/kg), a new selective dopamine-1 antagonist, significantly attenuated the vasodilator responses to fenoldopam in all three vascular beds. Pretreatment with propranolol failed to alter the vascular effects of fenoldopam, but reduced the tachycardia markedly. This study indicates that fenoldopam decreased regional vascular resistance in the renal, mesenteric and hindquarters vascular beds of the conscious SHR with the mesenteric vascular bed demonstrating the greatest reactivity. The vasodilation induced by fenoldopam in these vascular beds appeared to be due to stimulation of vascular dopamine-1 receptors.
在清醒、无束缚的自发性高血压大鼠(SHR)中,研究了选择性多巴胺-1激动剂非诺多泮对局部血流和血管阻力的影响。通过长期植入脉冲多普勒血流探头,对大鼠的肾、肠系膜和后肢血流进行测量。静脉注射非诺多泮(1 - 1000微克/千克)后,记录平均动脉压、心率和局部血流的最大变化。非诺多泮可使清醒SHR的动脉压呈剂量依赖性降低,并使心率增加。在所有剂量的非诺多泮作用下,肠系膜血流(最大增加69±10%)和肾血流(最大增加42±4%)均显著增加。在后肢,低剂量(1 - 30微克/千克)的非诺多泮可使血管阻力增加,但高剂量(100 - 1000微克/千克)时则降低。神经节阻断后,低剂量(10微克/千克)和高剂量(500微克/千克)的非诺多泮均可使后肢血管舒张。用甲氧氯普胺(20毫克/千克)或新型选择性多巴胺-1拮抗剂SCH 23390(30微克/千克)预处理,可显著减弱非诺多泮在所有三个血管床的血管舒张反应。用普萘洛尔预处理未能改变非诺多泮的血管效应,但可显著减轻心动过速。本研究表明,非诺多泮可降低清醒SHR肾、肠系膜和后肢血管床的局部血管阻力,其中肠系膜血管床的反应性最强。非诺多泮在这些血管床诱导的血管舒张似乎是由于刺激了血管多巴胺-1受体。